Metastatic Prostate Cancer—Does Treatment of the Primary Tumor Matter?

No AccessJournal of UrologyReview article1 Oct 2006Metastatic Prostate Cancer—Does Treatment of the Primary Tumor Matter? Gregory Swanson, Ian Thompson, Joseph Basler, and E. David Crawford Gregory SwansonGregory Swanson More articles by this author , Ian ThompsonIan Thompson More articles by this author , Joseph BaslerJoseph Basler More articles by this author , and E. David CrawfordE. David Crawford More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2006.06.069AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: In recent years there has been increased interest in adjuvant therapy for prostate cancer. This trend has engendered a tendency toward overlooking the issue of therapy to the primary tumor in advanced disease. We reviewed the effect of treating the principal disease bulk on overall treatment outcome in patients with advanced and metastatic cancer. Specifically we evaluated the role of surgical tumor cytoreduction. Materials and Methods: We performed a comprehensive literature review to evaluate the role of surgical debulking on the outcome of advanced cancer, including any published evidence supporting a benefit of this therapy for prostate cancer. Results: Even in cancers for which adjuvant chemotherapy and radiation are used liberally there is a clear benefit to optimal surgical debulking for local control and survival. The beneficial role of maximal surgical cytoreduction has been clearly demonstrated in advanced ovarian cancer and gastrointestinal carcinomatosis. Maximal debulking of brain, liver and lung metastasis has translated into longer survival. Removal of the primary tumor has been proved to increase survival in randomized trials of metastatic renal cell cancer. It appears that patients with node positive and possibly metastatic prostate cancer have a better response to androgen ablation with surgical removal of the gland. Conclusions: Surgical cytoreduction of cancer results in a more favorable and durable response to systemic therapy. It is reasonable to explore aggressive surgical therapy for advanced prostate cancer. References 1 : Surgical adjuvant chemotherapy of metastatic murine osteosarcoma. Int J Cancer1980; 25: 393. Google Scholar 2 : Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys1993; 26: 239. Google Scholar 3 : Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer1995; 75: 2727. Google Scholar 4 : Significance of margins of excision on breast cancer recurrence. Am J Clin Oncol (CCT)2002; 25: 438. Google Scholar 5 : Malignant tumors of the breast. In: Cancer. Edited by . Philadelphia: Lippincott Williams & Wilkins2001: 1651. Google Scholar 6 : Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet1998; 352: 930. Google Scholar 7 : The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol1994; 170: 974. Google Scholar 8 : Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol2002; 20: 1248. Google Scholar 9 : Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol2004; 5: 219. Google Scholar 10 : Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol2004; 22: 3475. Google Scholar 11 : Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol1993; 33: 583. Google Scholar 12 : Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin1999; 49: 231. Google Scholar 13 : Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer—Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer1996; 77: 675. Google Scholar 14 : Surgery of metastatic renal cell carcinoma and use of renal infarction. Semin Surg Oncol1988; 4: 124. Google Scholar 15 : Infarction-nephrectomy for metastatic renal carcinoma. Urology1985; 25: 248. Google Scholar 16 : Embolization and postinfarction nephrectomy in patients with primary metastatic renal adenocarcinoma. Eur Urol1987; 13: 251. Google Scholar 17 : Radical nephrectomy plus interferon alfa based immunotherapy compared with interferon alfa alone in metastatic renal cell carcinoma: a randomized trial. Lancet2001; 358: 966. Google Scholar 18 : Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med2001; 345: 1655. Crossref, Medline, Google Scholar 19 : Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. BJU Int2000; 86: 613. Google Scholar 20 : Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut1998; 43: 575. Google Scholar 21 : Radiation abscopal antitumor effect is mediated through p53. Cancer Res2003; 63: 1990. Google Scholar 22 : Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: potential role for host-tumor interaction. Cancer Res2000; 60: 2128. Google Scholar 23 : Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology2001; 58: 233. Google Scholar 24 : Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol1999; 161: 1223. Link, Google Scholar 25 : Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer. Br J Urol1997; 79: 226. Google Scholar 26 : Prognostic factors and survival in node-positive (N1) prostate cancer-a prospective study based on data from a Swedish population-based cohort. Eur Urol2003; 43: 627. Google Scholar 27 : Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer. Int J Radiat Oncol Biol Phys2002; 53: 1146. Google Scholar 28 : Androgen suppression plus radiation versus radiation alone for patients with D1 (pN1+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Int J Radiat Oncol Biol Phys1997; 28: 931. Google Scholar 29 : Risk of prostate cancer death in patients with lymph node metastasis. Cancer2001; 91: 66. Google Scholar 30 : Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer: results at 10 years of EST 3886. J Urol2003; 169: 396. abstract 1480. Google Scholar 31 : Radical prostatectomy for node-positive prostate cancer: impact of adjuvant hormone therapy and radiotherapy. J Urol2003; 169: 494. abstract 1850. Google Scholar 32 : Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. Urology1997; 50: 251. Google Scholar 33 : Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology1995; 45: 616. Crossref, Medline, Google Scholar 34 : Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet2002; 360: 103. Google Scholar 35 : Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol2003; 21: 1904. Google Scholar 36 : Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate specific antigen testing: 15-year outcome. BJU Int2005; 95: 751. Google Scholar 37 : Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol1982; 127: 1238. Link, Google Scholar 38 : Relationship between tumor size and the curability of metastatic prostate cancer by surgery alone or in combination with adjuvant chemotherapy. J Urol1988; 139: 1119. Abstract, Google Scholar 39 : Failure after primary radiation or surgery for prostate cancer: differences in response to androgen ablation. J Urol2004; 172: 525. Link, Google Scholar 40 : Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol2002; 168: 1008. Link, Google Scholar 41 : Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study. J Clin Oncol2004; 22: 4508. Google Scholar 42 : Temporal trends in radical prostatectomy complications from 1991 to 1998. J Urol2003; 169: 1443. Link, Google Scholar 43 : A reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel. Cancer Invest2000; 18: 191. Google Scholar 44 : Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev Urol2002; 4: 163. Google Scholar 45 : Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol2001; 159: 2159. Google Scholar 46 : Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology1994; 43: 675. Crossref, Medline, Google Scholar 47 : Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci USA1994; 91: 4673. Google Scholar 48 : Intracrine mechanism of estrogen synthesis in breast cancer. Biomed Pharmacother2003; 57: 460. Google Scholar 49 : Androgen metabolism in the human prostatic cancer cell line LNCaP. J Steroid Biochem Mol Biol1994; 51: 89. Google Scholar Departments of Radiation Oncology and Urology, University of Texas Health Science Center at San Antonio and Cancer Therapy and Research Center, San Antonio, Texas, and University of Colorado Health Science Center, Denver, Colorado© 2006 by American Urological AssociationFiguresReferencesRelatedDetails Volume 176Issue 4October 2006Page: 1292-1298 Advertisement Copyright & Permissions© 2006 by American Urological AssociationKeywordsprostateprostatic neoplasmsMetricsAuthor Information Gregory Swanson More articles by this author Ian Thompson More articles by this author Joseph Basler More articles by this author E. David Crawford More articles by this author Expand All Advertisement PDF downloadLoading ...